Why the study?
Cisplatin is frequently nephrotoxic, and SGLT2 inhibitors may protect the kidneys by reducing tubular cisplatin uptake.
Does SGLT2i exposure reduce acute kidney injury in patients with cancer and diabetes mellitus receiving cisplatin?
Cohort (n=288)
No
Does SGLT2i exposure reduce acute kidney injury in patients with cancer and diabetes mellitus receiving cisplatin?
Answers are grounded in this paper and cite their sources.
Continuation of SGLT2 inhibitors may offer kidney-protective effects against acute kidney injury in patients with cancer and diabetes mellitus undergoing cisplatin chemotherapy.
Introduction: Cisplatin is often nephrotoxic, frequently causing treatment interruptions or discontinuation. Mitigation includes dose adjustments, hydration, and supplemental magnesium. Sodium-glucose cotransporter-2 inhibitors (SGLT2is) may protect the kidneys by reducing tubular cells’ cisplatin uptake. We examined the potential kidney protective effect of SGLT2i in patients with cancer having diabetes mellitus receiving cisplatin. Methods: We conducted a single-center retrospective study of patients who received i.v. cisplatin from July 2017 to January 2024. Data extracted included comorbidities, variables associated with acute kidney injury (AKI; defined as ≥ 50% serum creatinine increase within 4 weeks), hyponatremia, hypomagnesemia, and anemia. Patients were divided according to SGLT2i exposure at cisplatin initiation and matched 1:1 using inverse propensity scores based on baseline characteristics. Descriptive statistics summarized baseline and outcome variables; parametric or nonparametric tests assessed group differences. Logistic regression and analysis of variance were used for further outcome analyses. Results: A total of 288 patients (n = 144 per group) were included. Median cisplatin dose per infusion was 40 mg/m2 with a median of 5 infusions, and median follow-up was 2 months. Incidence of AKI was lower in the SGLT2i group compared with controls (13.9% vs. 28.5%; odds ratio [OR]: 0.42; 95% confidence interval [CI]: 0.23–0.76). The SGLT2i group also showed higher mean estimated glomerular filtration rate (eGFR) at 3 months postcisplatin therapy, lower rate of hypomagnesemia, hyponatremia, and anemia than the control. Difference in hyponatremia was not statistically significant. Conclusion: Our findings suggest that continuation of SGLT2i may offer kidney-protective effects against AKI in patients with diabetes mellitus undergoing cisplatin chemotherapy. A well-designed randomized clinical trial is needed to validate this potential benefit.
No takes yet. Share an insight, caveat, or question.
Cintrón-García et al. (2026) conducted a cohort in Cancer with diabetes mellitus receiving cisplatin (n=288). Sodium-glucose cotransporter-2 inhibitors (SGLT2is) vs. Control (no SGLT2i exposure) was evaluated on Acute kidney injury (AKI; defined as ≥ 50% serum creatinine increase within 4 weeks) (OR 0.42, 95% CI 0.23–0.76).
Synapse has enriched 10 related papers. Consider them for comparative context: